Treatment effect modifiers in hospitalised patients with COVID-19 receiving remdesivir and dexamethasone

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Treatment effect modifiers in hospitalised patients with COVID-19 receiving remdesivir and dexamethasone. / Leding, Cæcilie; Bodilsen, Jacob; Brieghel, Christian; Harboe, Zitta Barrella; Helleberg, Marie; Holm, Claire; Israelsen, Simone Bastrup; Jensen, Janne; Jensen, Tomas Østergaard; Johansen, Isik Somuncu; Johnsen, Stine; Kirk, Ole; Lindegaard, Birgitte; Meyer, Christian Niels; Mohey, Rajesh; Pedersen, Lars; Nielsen, Henrik; Nielsen, Stig Lønberg; Omland, Lars Haukali; Podlekareva, Daria; Ravn, Pernille; Starling, Jonathan; Storgaard, Merete; Søborg, Christian; Søgaard, Ole Schmeltz; Tranborg, Torben; Wiese, Lothar; Worm, Signe Heide Westring; Christensen, Hanne Rolighed; Benfield, Thomas.

In: Infectious Diseases, Vol. 55, No. 5, 2023, p. 351-360.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Leding, C, Bodilsen, J, Brieghel, C, Harboe, ZB, Helleberg, M, Holm, C, Israelsen, SB, Jensen, J, Jensen, TØ, Johansen, IS, Johnsen, S, Kirk, O, Lindegaard, B, Meyer, CN, Mohey, R, Pedersen, L, Nielsen, H, Nielsen, SL, Omland, LH, Podlekareva, D, Ravn, P, Starling, J, Storgaard, M, Søborg, C, Søgaard, OS, Tranborg, T, Wiese, L, Worm, SHW, Christensen, HR & Benfield, T 2023, 'Treatment effect modifiers in hospitalised patients with COVID-19 receiving remdesivir and dexamethasone', Infectious Diseases, vol. 55, no. 5, pp. 351-360. https://doi.org/10.1080/23744235.2023.2187081

APA

Leding, C., Bodilsen, J., Brieghel, C., Harboe, Z. B., Helleberg, M., Holm, C., Israelsen, S. B., Jensen, J., Jensen, T. Ø., Johansen, I. S., Johnsen, S., Kirk, O., Lindegaard, B., Meyer, C. N., Mohey, R., Pedersen, L., Nielsen, H., Nielsen, S. L., Omland, L. H., ... Benfield, T. (2023). Treatment effect modifiers in hospitalised patients with COVID-19 receiving remdesivir and dexamethasone. Infectious Diseases, 55(5), 351-360. https://doi.org/10.1080/23744235.2023.2187081

Vancouver

Leding C, Bodilsen J, Brieghel C, Harboe ZB, Helleberg M, Holm C et al. Treatment effect modifiers in hospitalised patients with COVID-19 receiving remdesivir and dexamethasone. Infectious Diseases. 2023;55(5):351-360. https://doi.org/10.1080/23744235.2023.2187081

Author

Leding, Cæcilie ; Bodilsen, Jacob ; Brieghel, Christian ; Harboe, Zitta Barrella ; Helleberg, Marie ; Holm, Claire ; Israelsen, Simone Bastrup ; Jensen, Janne ; Jensen, Tomas Østergaard ; Johansen, Isik Somuncu ; Johnsen, Stine ; Kirk, Ole ; Lindegaard, Birgitte ; Meyer, Christian Niels ; Mohey, Rajesh ; Pedersen, Lars ; Nielsen, Henrik ; Nielsen, Stig Lønberg ; Omland, Lars Haukali ; Podlekareva, Daria ; Ravn, Pernille ; Starling, Jonathan ; Storgaard, Merete ; Søborg, Christian ; Søgaard, Ole Schmeltz ; Tranborg, Torben ; Wiese, Lothar ; Worm, Signe Heide Westring ; Christensen, Hanne Rolighed ; Benfield, Thomas. / Treatment effect modifiers in hospitalised patients with COVID-19 receiving remdesivir and dexamethasone. In: Infectious Diseases. 2023 ; Vol. 55, No. 5. pp. 351-360.

Bibtex

@article{453ee48eadf747c59c453d79fdb612ea,

title = "Treatment effect modifiers in hospitalised patients with COVID-19 receiving remdesivir and dexamethasone",

abstract = "Background: The combined effectiveness of remdesivir and dexamethasone in subgroups of hospitalised patients with COVID-19 is poorly investigated. Methods: In this nationwide retrospective cohort study, we included 3826 patients with COVID-19 hospitalised between February 2020 and April 2021. The primary outcomes were use of invasive mechanical ventilation and 30-day mortality, comparing a cohort treated with remdesivir and dexamethasone with a previous cohort treated without remdesivir and dexamethasone. We used inverse probability of treatment weighting logistic regression to assess associations with progression to invasive mechanical ventilation and 30-day mortality between the two cohorts. The analyses were conducted overall and by subgroups based on patient characteristics. Results: Odds ratio for progression to invasive mechanical ventilation and 30-day mortality in individuals treated with remdesivir and dexamethasone compared to treatment with standard of care alone was 0.46 (95% confidence interval, 0.37–0.57) and 0.47 (95% confidence interval, 0.39–0.56), respectively. The reduced risk of mortality was observed in elderly patients, overweight patients and in patients requiring supplemental oxygen at admission, regardless of sex, comorbidities and symptom duration. Conclusions: Patients treated with remdesivir and dexamethasone had significantly improved outcomes compared to patients treated with standard of care alone. These effects were observed in most patient subgroups.",

keywords = "30-day mortality, Clinical outcome, COVID-19, dexamethasone, remdesivir, SARS-CoV-2",

author = "C{\ae}cilie Leding and Jacob Bodilsen and Christian Brieghel and Harboe, {Zitta Barrella} and Marie Helleberg and Claire Holm and Israelsen, {Simone Bastrup} and Janne Jensen and Jensen, {Tomas {\O}stergaard} and Johansen, {Isik Somuncu} and Stine Johnsen and Ole Kirk and Birgitte Lindegaard and Meyer, {Christian Niels} and Rajesh Mohey and Lars Pedersen and Henrik Nielsen and Nielsen, {Stig L{\o}nberg} and Omland, {Lars Haukali} and Daria Podlekareva and Pernille Ravn and Jonathan Starling and Merete Storgaard and Christian S{\o}borg and S{\o}gaard, {Ole Schmeltz} and Torben Tranborg and Lothar Wiese and Worm, {Signe Heide Westring} and Christensen, {Hanne Rolighed} and Thomas Benfield",

note = "Publisher Copyright: {\textcopyright} 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.",

year = "2023",

doi = "10.1080/23744235.2023.2187081",

language = "English",

volume = "55",

pages = "351--360",

journal = "Infectious Diseases",

issn = "2374-4235",

publisher = "Taylor & Francis",

number = "5",

}

RIS

TY - JOUR

T1 - Treatment effect modifiers in hospitalised patients with COVID-19 receiving remdesivir and dexamethasone

AU - Leding, Cæcilie

AU - Bodilsen, Jacob

AU - Brieghel, Christian

AU - Harboe, Zitta Barrella

AU - Helleberg, Marie

AU - Holm, Claire

AU - Israelsen, Simone Bastrup

AU - Jensen, Janne

AU - Jensen, Tomas Østergaard

AU - Johansen, Isik Somuncu

AU - Johnsen, Stine

AU - Kirk, Ole

AU - Lindegaard, Birgitte

AU - Meyer, Christian Niels

AU - Mohey, Rajesh

AU - Pedersen, Lars

AU - Nielsen, Henrik

AU - Nielsen, Stig Lønberg

AU - Omland, Lars Haukali

AU - Podlekareva, Daria

AU - Ravn, Pernille

AU - Starling, Jonathan

AU - Storgaard, Merete

AU - Søborg, Christian

AU - Søgaard, Ole Schmeltz

AU - Tranborg, Torben

AU - Wiese, Lothar

AU - Worm, Signe Heide Westring

AU - Christensen, Hanne Rolighed

AU - Benfield, Thomas

PY - 2023

Y1 - 2023

N2 - Background: The combined effectiveness of remdesivir and dexamethasone in subgroups of hospitalised patients with COVID-19 is poorly investigated. Methods: In this nationwide retrospective cohort study, we included 3826 patients with COVID-19 hospitalised between February 2020 and April 2021. The primary outcomes were use of invasive mechanical ventilation and 30-day mortality, comparing a cohort treated with remdesivir and dexamethasone with a previous cohort treated without remdesivir and dexamethasone. We used inverse probability of treatment weighting logistic regression to assess associations with progression to invasive mechanical ventilation and 30-day mortality between the two cohorts. The analyses were conducted overall and by subgroups based on patient characteristics. Results: Odds ratio for progression to invasive mechanical ventilation and 30-day mortality in individuals treated with remdesivir and dexamethasone compared to treatment with standard of care alone was 0.46 (95% confidence interval, 0.37–0.57) and 0.47 (95% confidence interval, 0.39–0.56), respectively. The reduced risk of mortality was observed in elderly patients, overweight patients and in patients requiring supplemental oxygen at admission, regardless of sex, comorbidities and symptom duration. Conclusions: Patients treated with remdesivir and dexamethasone had significantly improved outcomes compared to patients treated with standard of care alone. These effects were observed in most patient subgroups.

AB - Background: The combined effectiveness of remdesivir and dexamethasone in subgroups of hospitalised patients with COVID-19 is poorly investigated. Methods: In this nationwide retrospective cohort study, we included 3826 patients with COVID-19 hospitalised between February 2020 and April 2021. The primary outcomes were use of invasive mechanical ventilation and 30-day mortality, comparing a cohort treated with remdesivir and dexamethasone with a previous cohort treated without remdesivir and dexamethasone. We used inverse probability of treatment weighting logistic regression to assess associations with progression to invasive mechanical ventilation and 30-day mortality between the two cohorts. The analyses were conducted overall and by subgroups based on patient characteristics. Results: Odds ratio for progression to invasive mechanical ventilation and 30-day mortality in individuals treated with remdesivir and dexamethasone compared to treatment with standard of care alone was 0.46 (95% confidence interval, 0.37–0.57) and 0.47 (95% confidence interval, 0.39–0.56), respectively. The reduced risk of mortality was observed in elderly patients, overweight patients and in patients requiring supplemental oxygen at admission, regardless of sex, comorbidities and symptom duration. Conclusions: Patients treated with remdesivir and dexamethasone had significantly improved outcomes compared to patients treated with standard of care alone. These effects were observed in most patient subgroups.

KW - 30-day mortality

KW - Clinical outcome

KW - COVID-19

KW - dexamethasone

KW - remdesivir

KW - SARS-CoV-2

UR - http://www.scopus.com/inward/record.url?scp=85150616242&partnerID=8YFLogxK

U2 - 10.1080/23744235.2023.2187081

DO - 10.1080/23744235.2023.2187081

M3 - Journal article

C2 - 36905638

AN - SCOPUS:85150616242

VL - 55

SP - 351

EP - 360

JO - Infectious Diseases

JF - Infectious Diseases

SN - 2374-4235

IS - 5

ER -

ID: 367355748